Related Experiment Video

Updated: May 31, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Evaluating Drug-Target Complexes in Therapeutic Monoclonal Antibodies Using A4F-MALS: Implications for Drug

Nina Liu1, Donald Kotowski1,2, Eric T Ong1

  • 1Product Biochemistry, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA, regeneron.com.

Journal of Immunology Research
|May 29, 2026
PubMed

Therapeutic monoclonal antibodies (mAbs) remain an important segment of the biopharmaceutical industry, delivering highly effective and targeted responses against human diseases. The immune complexes formed between a therapeutic mAb and its target antigens may affect efficacy, clearance (pharmacokinetics), and immunogenicity. As such, immune complexes represent an important biophysical property to characterize during drug product screening and development. In this study, we leverage asymmetric flow field-flow fractionation coupled with multiangle light scattering (A4F-MALS) to evaluate the size distribution of complexes formed between a panel of therapeutic mAbs directed against a common target antigen. The inclusion of this analysis enables important insights that can guide the screening of therapeutic candidates during lead candidate assessments, as well as risk mitigation to help better inform clinical design strategy.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...